by ARCHISHA MUKHERJEE

Chinese biotechs advancing clinical programs, securing approvals and executing licensing deals at dizzying new speed
The continuous stream of drug approvals by Chinese pharmaceutical companies should be a source of awe to any global innovation investor. There are multiple reasons that have led to the current point. However, one key contributor is China’s drug approval policy transformation, which is one of the most under-discussed and massively impactful policy narratives of our era.
The history of the global pharmaceutical industry has largely been a monologue, spoken by the West and listened to by the East. For the better part of the post-war era, the United States, through the engines of the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), served as the world’s laboratory.
In this established orthodoxy, which also included a handful of companies from Japan and Europe, China entered decades later, becoming the world’s factory. In the first phase, it became a massive but fundamentally replicative engine designed to produce volume rather than value.
This dynamic was underpinned by a regulatory lag so severe that it functioned as a non-tariff trade barrier; drugs invented in Cambridge or Basel would typically arrive in Beijing or Shanghai five to seven years after their Western debut.
This delay, known colloquially as the “drug lag,” effectively imposed a “China-last” penalty on the world’s largest aging demographic, rendering the Chinese patient population a secondary consideration in the global R&D calculus.
That era is demonstrably over. It did not end with a whimper, nor was it the result of a slow, organic drift of market forces. It ended with a calculated, statutory, and industrial restructuring of the Chinese state’s relationship with biology.
We are currently witnessing the results of a decade-long project of Acceleration by Design, a deliberate strategy to transform the regulatory review process from a discretionary gatekeeping function into a mandatory conveyance system for innovation.
The data emerging from 2024 and early 2025 confirms a tectonic inversion in the global biopharmaceutical hierarchy. For the first time in history, the sheer velocity and volume of China’s regulatory apparatus have not merely caught up to Western standards but, in specific metrics of efficiency and output, have bypassed them.
In 2024, China’s NMPA approved 83 new drugs (excluding TCM), a 12% year-on-year increase—significantly outpacing the FDA’s 50 novel medicines. Of these, 46 were Class 1/1.1 innovative drugs (the regulatory classification for drugs not previously marketed anywhere), while 48 qualified as first-in-class by mechanism of action, covering high-complexity modalities including bispecific antibodies, ADCs, and novel small molecules.
Average review times collapsed from 663 days in 2017 to approximately 105 days in 2024, an 84% reduction.

This report serves as a deep-dive forensic audit of this transformation. By verifying internal regulatory documents and synthesizing external market data, we dissect the seven structural pillars of the “Accelerationist State” and project the consequences of a world where the East no longer waits for the West’s medicine.
The Cradle for more





